(Q37610176)

21 August 2017

title

Glatiramer acetate for multiple sclerosis: a comprehensive review of mechanisms and clinical efficacy (English)

1 reference

21 August 2017

0 references

Marina Zvartau-Hind

1

1 reference

21 August 2017

Christina Caon

2

1 reference

21 August 2017

Rana Zabad

3

1 reference

21 August 2017

Alexandros Tselis

4

1 reference

21 August 2017

Robert Lisak

5

1 reference

21 August 2017

Omar Khan

6

1 reference

21 August 2017

publication date

1 May 2002

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

21 August 2017

published in

1 reference

21 August 2017

volume

2

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

285-294

1 reference

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

A comparison of observational studies and randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2.3.285

21 January 2018

Identifiers

DOI

10.1586/14737175.2.3.285

1 reference

21 August 2017

1 reference